Angiogenic cytokines, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and angiogenin, are candidates for the induction of pleural effusions because they have been implicated in the induction of neovascularization, vascular permeability, and hemorrhage both in the inflammatory process and in tumor progression. Thus, we hypothesized that these angiogenic factors in effusion might be involved in the clinical manifestation of malignant pleural disease. We measured the levels of VEGF, bFGF, and angiogenin in pleural effusions and sera from 40 patients. Pleural effusions due to malignancy (1,350 pg/ml) contained significantly higher levels of VEGF than effusions due to inflammatory diseases (102 pg/ml; p = 0.034). Furthermore, hemorrhagic effusions showed significantly higher VEGF levels (1,942 pg/ml) than non-hemorrhagic effusions (202 pg/ml; p = 0.016) in malignant patients. In contrast, neither bFGF nor angiogenin were correlated with any clinical manifestation of pleural effusion. Immunohistochemical study revealed that malignant cells in the pleura were stained with anti-VEGF antibody. Our data suggest that VEGF secreted from tumor cells may be involved in the accumulation of pleural effusion in malignancy, and that increased levels of VEGF may induce hemorrhagic effusion.

Keywords:
Angiogenic factor, Basic fibroblast growth factor, Fibroblast growth factor, Malignant pleural effusion, Vascular endothelial growth factor
1.
Gursel G, Gokcora N, Elbeg S, Samurkasoglu B, Ekim N: Tumor necrosis factor-alpha (TNF-alpha) in pleural fluids. Tuber Lung Dis 1995;76:370–371.
2.
Ikubo A, Morisaki T, Katano M, Kitsuki H, Anan K, Uchiyama A, Tanaka M, Torisu M: A possible role of TGF-beta in the formation of malignant effusions. Clin Immunol Immunopathol 1995;77:27–32.
3.
Yeo KT, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF, Yeo TK: Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 1993;53:2912–2918.
4.
Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marme D, Gastl G: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85:178–187.
5.
Cheng D, Rodriguez RM, Perkett EA, Rogers J, Bienvenu G, Lappalainen U, Light RW: Vascular endothelial growth factor in pleural fluid. Chest 1999;116:760–765.
6.
Thickett DR, Armstrong L, Millar AB: Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999;54:707–710.
7.
Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S: Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer Cancer Immunol Immunother 1999;48:396–400.
8.
Zebrowski BK, Yano S, Liu W, Shaheen RM, Hicklin DJ, Putnam JB, Ellis LM: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1995;5:3364–3368.
9.
Ceyhan BB, Ozgun S, Celikel T, Yalcin M, Koc M: IL-8 in pleural effusion. Respir Med 1996;90:215–221.
10.
Luo JC, Toyoda M, Shibuya M: Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 1998;58:2594–2600.
11.
Rossi GA, Sacco O: Cells of the mesothelial space; in Crystal RG, Barnes PJ, Weibel ER (eds): The Lung: Scientific Foundations, ed 2. Philadelphia, Lippincott-Raven, 1997, pp 971–980.
12.
Taylor JM: Kendall’s and Spearman’s correlation coefficients in the presence of a blocking variable. Biometrics 1987;43:409–416.
13.
Friesel RE, Maciag T: Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction. FASEB J 1995;9; 919–925.
14.
Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM: Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999;286:2511–2514.
15.
Cheng SY, Nagane M, Huang HS, Cavenee WK: Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci USA 1997;94:12081–12087.
16.
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480–1487.
17.
Pepper MS, Ferrara N, Orci L, Montesano R: Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991;181:902–906.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.